|Cleveland BioLabs, Inc.|
73 High Street
United States - Map
Cleveland BioLabs, Inc., a biopharmaceutical company, focuses on developing pharmaceuticals designed to address diseases with unmet medical need. Its lead drug candidate includes Entolimod, a Toll-like receptor 5 (TLR5) agonist, which is used for the prevention of death from acute radiation syndrome, and is used as an oncology drug. The company is also developing CBLB612, a pharmacologically optimized synthetic molecule that structurally mimics naturally occurring lipopeptides of Mycoplasma, and activates NF-kB pro-survival and immunoregulatory signaling pathways; CBL0137, a small molecule with a multi-targeted mechanism of action used for the treatment of various types of cancer; and Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. It has strategic partnerships with The Cleveland Clinic Foundation and Roswell Park Cancer Institute. The company was founded in 2003 and is headquartered in Buffalo, New York.
|Dr. Yakov N. Kogan Ph.D., MBA,
Co-Founder, Chief Exec. Officer and Director
|Dr. Langdon L. Miller M.D.,
Pres and Chief Medical Officer
|Mr. C. Neil Lyons CPA,
Chief Financial Officer, Exec. VP and Corp. Sec.
|Dr. Andrei V. Gudkov Ph.D., D.Sci.,
Co-Founder, Chief Scientific Officer and Director
|Ms. Rachel Levine ,
VP of Investor Relations
|Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|